Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling

Journal of Clinical Investigation

Volumn 125, Issue 3, 2015, Pages 1129-1146

  Quinn, Kylie M ^a,h   Zak, Daniel E ^b   Costa, Andreia ^a,i   Yamamoto, Ayako ^a   Kastenmuller, Kathrin ^a,j   Hill, Brenna J ^a   Lynn, Geoffrey M ^a   Darrah, Patricia A ^a   Lindsay, Ross W B ^a,k   Wang, Lingshu ^a   Cheng, Cheng ^a   Nicosia, Alfredo ^c,d,e   Folgori, Antonella ^c   Colloca, Stefano ^c   Cortese, Riccardo ^f   Gostick, Emma ^g   Price, David A ^g   Gall, Jason G D ^a   Roederer, Mario ^a   Aderem, Alan ^b   Seder, Robert A ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c ReiThera Srl ^*  (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Keires AG   (Switzerland)

^g CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j UNIVERSITY OF BONN   (Germany)

^k INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN P 15095; INTERFERON; PROTEIN; STIMULATOR OF INTERFERON GENE PROTEIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MPYS PROTEIN, MOUSE; PATTERN RECOGNITION RECEPTOR; RECOMBINANT VACCINE; TRANSCRIPTOME; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG POTENCY; GENE ACTIVATION; INNATE IMMUNITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VACCINATION; ADENOVIRIDAE; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; C57BL MOUSE; CROSS PRESENTATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ADENOVIRIDAE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; GENE PRODUCTS, GAG; IMMUNITY, INNATE; INTERFERONS; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84924067611     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78280     Document Type: Article

References (67)

1. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vacc ine carrier. Virology. 1996;219(1):220-227.
2. Vogels R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77(15):8263-8271.
3. Kahl CA, et al. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector b ased on rare human serotype 28. Vaccine. 2010; 28(35):5691-5702.
4. Farina SF, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001;75(23):11603-11613.
5. Xiang Z, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol. 2002;76(6):2667-2675.
6. Peruzzi D, et al. A novel chimpanzee serotypebased adenoviral vector as delivery tool for cancer vaccines. Vaccine. 2009;27(9):1293-1300.
7. Colloca S, et al. Vaccine vec tors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Trans Med. 2012;4(115):115ra112.
8. Abbink P, et al. Comparative seroprevalence a nd immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81(9):4654-4663.
9. Quinn KM, et al. Comparative analysis of the magnitude, qualit y, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013;190(6):2720-2735.
10. Liu J, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009;457(7225):87-91.
11. Stanley DA, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126-1129.
12. Hensley SE, et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther. 2007;15(2):393-403.
13. Varnavski AN, Schlienger K, Bergelson JM, Gao G-P, Wilson JM. Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Hum Gene Ther. 2003;14(6):533-544.
14. Johnson MJ, et al. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol. 2012;188(12):6109-6118.
15. Teigler JE,Iampietro MJ,Barouch DH Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys J Virol. 2012 86, 18, 9590-9598.
16. Shoji M, et al. Type-I IFN signaling is required for the induction of antigen-specific CD8(+) T cell responses by adenovirus vector vac cine in the gut-mucosa. Biochem Biophys Res Commun. 2012;425(1):89-93.
17. Hartman ZC, et al. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and ad aptive immune responses in vivo. J Virol. 2007;81(4):1796-1812.
18. Appledorn DM, Patial S, Godbehere S, Parameswaran N, Amalfitano A. TRIF, and TRIF-interacting TLRs differentially modu late several adenovirus vector-induced immune responses. J Innate Imm. 2009;1(4):376-388
19. Rhee EG, et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol. 2011;85(1):315-323.
20. Lindsay RWB, et al. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligome rization domain-like receptor signaling. J Immunol. 2010;185(3):1513-1521.
21. Muruve DA, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452(7183):103-107.
22. Quinn KM, et al. Coadministration of polyinosinic: polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhanc es HIV gag-specific T cell immunity. J Immunol. 2013;191(10):5085-5096.
23. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003;9(11):1408-1412.
24. Hildner K, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322(5904):1097-1100.
25. Edelson BT, et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8?+ conventional dendritic cells. J Exp Med. 2010;207(4):823-836.
26. Zak DE, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A. 2012;109(50):E3503-E3512.
27. Nakaya HI, Pulendran B. Systems vaccinology: its promise and challenge for HIV vaccine development. Curr Opin HIV AIDS. 2012;7(1):24-31.
28. Obermoser G, et al. Systems scale interactive exploration reve als quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity. 2013;38(4):831-844.
29. Jojic V, et al. Identification of transcriptional regulators in the mouse immune system. Nat Immunol. 2013;14(6):633-643.
30. Li S, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. 2014;15(2):195-204.
31. Querec TD, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116-125.
32. Nak aya HI, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011;12(8):786-795.
33. Li XL, Blackford JA, Hassel BA. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol. 1998;72(4):2752-2759.
34. Offermann MK, et al. Activation of the double-stranded-RNA-Activated protein kinase and induction of vascular cell adhesion molecule-1 by poly (I).poly (C) in endothelial cells. Eur J Biochem. 1995;232(1):28-36.
35. Liberzon A, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-1740.
36. Mü ller U, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918-1921.
37. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674-678.
38. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461(7265):788-792.
39. Ablasser A, et al. cGAS produces a 2?-5?-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498(7454):380-384.
40. Burdette DL, et al. S TING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478(7370):515-518.
41. Holm CK, et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat Immunol. 2012;13(8):737-743.
42. Stein SC, Falck-Pedersen E. Sensing adenovirus infection: activation of interferon regulatory factor 3 in RAW 264.7 cells. J Virol. 2012;86(8):4527-4537.
43. Lam E, Stein S, Falck-Pedersen E. Adenovirus detection by the cGAS/STING/TBK1 DNA sensing cascade. J Virol. 2013;88(2):974-981.
44. Schoggins JW, et al. Pan-viral specificity of IFNinduced genes reveals new roles for cGAS in innate immunity. Nature. 2013;505(7485):691-695.
45. Sauer J-D, et al. The N-ethyl-N-nitrosoureainduced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Imm. 2011;79(2):688-694.
46. Bassett JD, et al. CD8+ T-cell expansion and maint enance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. Blood. 2011;117(4):1146-1155.
47. Aparicio O, et al. Adenoviru s VA RNA-derived miRNAs target cellular genes involved in cell growth, gene expression and DNA repair. Nucleic Acids Res. 2010;38(3):750-763.
48. Perreau M, et al. The number of Toll-like receptor 9-Agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. J Virol. 2012;86(11):6279-6285.
49. Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal. 2012;5(214):ra20.
50. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637-650.
51. Starbeck-Miller GR, Xue H-H, Harty JT. IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-Affinity IL-2 signaling in vivo. J Exp Med. 2014; 211(1):105-120.
52. Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immuno l. 2006;177(3):1746-1754.
53. Keppler SJ, Rosenits K, Koegl T, Vucikuja S, Aichele P. Signal 3 cytokines as modulators of primary immune responses during infections: the interplay of type I I FN and IL-12 in CD8 T cell responses. PLoS One. 2012;7(7):e40865.
54. Crouse J, et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity. 2014;40(6):961-973.
55. Xu HC, et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity. 2014;40(6):949-960.
56. Frenz T, et al. Concomitant type I IFN receptortriggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. Eur J Immunol. 2010;40(10):2769-2777.
57. Kasten mü ller K, et al. Protective T cell immunity in mice following protein-TLR7/8 agonistconjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest. 2011;121(5):1782-1796.
58. Le Bon A,et al Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon Nat Immunol. 2003 4 10, 1009-1015.
59. Johnson MJ, et al. Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression. Vaccine. 2014;32(6):717-724.
60. Archer KA, Durack J, Portnoy DA. STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog. 2014;10(1):e1003861.
61. Loré K, et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vecto rs and stimulate polyfunctional memory T cell responses. J Immunol. 2007;179(3):1721-1729.
62. Geisbert TW, et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol. 2010;84(19):10386-10394.
63. S mall JC, Haut LH, Bian A, Ertl HCJ. The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses. J Leuk Biol. 2014;96(5):821-831.
64. C askey M, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011;208(12):2357-2366.
65. Liu J, et al. Modulation of DNA v accine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J Virol. 2006;80(24):11991-11997.
66. Zak DE, et al. Systems analysis identifies an essential role for SHANK-Associated RH doma in-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses. Proc Natl Acad Sci U S A. 2011;108(28):11536-11541.
67. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-210.